Bachem and Axon Neuroscience sign finished dosage form contract

Published: 3-Apr-2013
Manufacturing Ingredients Pharmaceutical

Axon product targets Alzheimer’s disease


Bachem is to manufacture an investigational API for Slovakian biotechnology firm Axon Neuroscience and supply it as a finished dosage form under Bachem’s Clinalfa brand. Axon’s product, which targets Alzheimer’s disease, consists of a peptide-protein conjugate and will enter Phase I clinical trials in Europe.

Roman Sivak, CEO of Axon Neuroscience, said: ‘We have chosen Bachem because of its stellar reputation for quality work and the wide range of services it provides, spanning peptide API production to conjugates and fill finish activities.’

Bachem, headquartered in Bubendorf, Switzerland, specialises in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes.

  • Companies:
  • Bachem
  • Axon Neuroscience
See more

You may also like

Manufacturing

LEWA optimises Bachem's oligonucleotide production through inline dilution system

Read more
This system allows for a flow rate of 2,500 L per hour, while also enabling flexible buffer production with varying flow rates

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. CDMO market trends and dynamics The rise of the embedded model

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

LEWA optimises Bachem's oligonucleotide production through inline dilution system

This system allows for a flow rate of 2,500 L per hour, while also enabling flexible buffer production with varying flow rates
Manufacturing

Achieving sustainable oligonucleotide production at an industrial scale

Sustainability is becoming increasingly important in pharmaceutical manufacturing, so Bachem's Philipp Markolin shares some insight into planet-friendly peptide and oligonucleotide manufacturing
Distribution

Ensuring pharma supply chain resilience amidst a dynamic global landscape

Global events can significantly disrupt the phamaceutical supply chain, but companies must take steps to ensure it remains consistent in times of adversity, explains Pascal Degen, Vice President of Global Supply Chain Management for Bachem
Manufacturing

Innovation in generics: increased efficiency through peptide API synthesis expertise

Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Manufacturing

Innovating TIDE production with continuous chromatography

The advancements now allow for purification of up to two tons of crude peptides and kilograms of oligonucleotides, while meeting Good Manufacturing Practice (GMP) standards
Manufacturing

Swiss biomanufacturing sector continues to thrive in 2023

Seigfried, Lonza, ten23 health, Bachem and Dottikon all announce major expansions
Manufacturing

Strategic alliances in pharma and biotech: innovation through co-operation

It can often be mutually beneficial for two business parties to pool resources and agree to share facets of operation including manufacturing capabilities or technologies. These collaborations, known as strategic alliances, help each party work towards individual goals while driving innovation
Subscribe now